Table 6. Immunophenotyping results for the patients when Matutes Score was not available
|
Patient number |
Ly 109/L |
CD 45+ % |
CD 3+ % |
CD 3- CD56+ % |
CD 19+ % |
CD 20+ % |
К % |
λ% |
К/λ |
Other characteristics |
Conclusion |
|
6 |
10.3 |
++ 20 |
56 |
34 |
9 |
4 |
70 |
30 |
2.3 |
Plasma cells |
Myeloma or Plasma cell leukemia |
|
7 |
3.6 |
++ 18 |
51 |
15 |
34 |
34 |
97 |
3 |
32.3 |
Lymphocyte, Plasmocyte, Ig M |
Waldenström disease |
|
8 |
50.9 |
++ 89 |
8 |
86 |
5 |
5 |
59 |
41 |
1.4 |
CD 3-CD16+ |
NK Proliferation |
|
9 |
35.2 |
± 65 |
0 |
|
0 |
0 |
|
|
|
c MPO-, CD 34+, HLA-DR+, CD 117-, CD 33- |
Acute leukemia |
|
10 |
70.0 |
± 80 |
50 |
|
0 |
0 |
|
|
|
c MPO-, c CD3+, HLA-DR+, CD 5+, CD 7+ |
T-cell ALL |
|
11 |
20.5 |
± 15 |
8 |
- |
5 |
|
|
|
|
cMPO+, CD 34+, HLA-DR+, CD 33+ |
AML |
|
12 |
7.4 |
± 20 |
15 |
|
28 |
|
|
|
|
Myeloblast/ cMPO+, CD 34+, HLA-DR+, CD 33+ |
AML-M2 |
Abbreviation: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Ly, lymphocytes.